The use of protein biomarkers in the diagnosis of NSCLC will be one of the critical MEK inhibitors market trends driving market growth. The level of protein biomarkers such as pro-gastrin-releasing peptide (ProGRP), C-reactive protein (CRP), carcinoembryonic antigen (CEA), NSE, cytokeratin-19 fragment 21-1 (CYFRA21-1), squamous-cell carcinoma antigen (SCCA), and trehalose-6-phosphate synthase (TPS) is high among patients with NSCLC. The treatment of NSCLC involves protein biomarker testing of tumor samples followed by therapies in the first-line testing. The use of protein biomarkers is preferred for the diagnosis of NSCLC because of its high diagnostic efficacy. The use of predictive protein biomarkers also minimizes the treatment cost and adverse effects associated with the treatment. MEK inhibitors are generally the most preferred types of drugs for the treatment of NSCLC associated with BRAF mutation. The advances in protein biomarker testing for the diagnosis of NSCLC will have a positive impact on the growth of the MEK inhibitors market.
The high target affinity and specificity of MEK inhibitors will also contribute to the growth of the market. Approved therapies for the treatment of advanced or metastatic carcinomas, such as melanoma and NSCLC, have low patient adherence because of their several side effects. However, MEK inhibitors have emerged as one of the ideal solutions for cancer treatments because of their high efficacy in oncology applications. MEK inhibitors exhibit higher efficacy than conventional treatments as they act directly on the target. MEK inhibitors also help in decreasing the growth of tumors in people with metastatic melanoma by hindering the activity of MEK and BRAF kinases. The promising results demonstrated by MEK inhibitors in oncology have encouraged researchers to expand its applications to other invasive cancer indications, such as colorectal cancer. The high target affinity and specificity of MEK inhibitors will boost its popularity among end-users and fuel the growth of the market at a CAGR of over 8% during the forecast period.
Top MEK Inhibitors Companies Covered in this Market Research Report
The global MEK inhibitors market is concentrated. To help clients improve their market position, this report provides an analysis of the market’s competitive landscape and offers information on the products offered by various companies. Moreover, this MEK inhibitors market analysis report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading MEK inhibitors companies, including:
F. Hoffmann-La Roche Ltd.
Ono Pharmaceutical Co. Ltd.
MEK Inhibitors Market Segmentation Based on Product
The MEKINIST segment will account for the highest MEK inhibitors market share. The increasing sale of MEKINIST because of the expansion of research indications focusing on new patient pools will be one of the significant factors driving the growth of the MEK inhibitors market in this segment. This market research report provides an accurate prediction of the contribution of all the segments to the growth of the MEK inhibitors market size.
MEK Inhibitors Market Segmentation Based on Geographic Region
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest MEK inhibitors market share throughout the forecast period. The rising prevalence of several cancer indications and the increasing sales of approved MEK inhibitors are responsible for MEK inhibitors market growth in this segment.
Key Highlights of the Global MEK Inhibitors Market for the Forecast Period 2019-2023
CAGR of the market during the forecast period 2019-2023
Detailed information on factors that will accelerate the growth of the MEK inhibitors market during the next five years
Precise estimation of the global MEK inhibitors market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the MEK inhibitors industry across Asia, Europe, North America, and ROW
A thorough analysis of the market’s competitive landscape and detailed information on several vendors
Comprehensive details of factors that will challenge the growth of MEK inhibitors companies
We can help! Our analysts can customize this market research report to meet your requirements.Get in touch